{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:55:57Z","timestamp":1787583357546,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["446653\/2024-1"],"award-info":[{"award-number":["446653\/2024-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","award":["19\/2022"],"award-info":[{"award-number":["19\/2022"]}],"id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003545","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Inova\u00e7\u00e3o","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jneuroim.2025.578752","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:05:37Z","timestamp":1757347537000},"page":"578752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cranial neuropathies related to immune checkpoint inhibitors"],"prefix":"10.1016","volume":"409","author":[{"given":"Gabriel de Deus","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius de Oliveira","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Schlindwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed Cleso Pereira","family":"de Souza Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Fanine","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Petry","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Higor","family":"Campezato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vinicius Magno","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jneuroim.2025.578752_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578752_bb0010","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.3174\/ajnr.A4581","article-title":"Ipilimumab therapy for melanoma: a mimic of leptomeningeal metastases","volume":"36","author":"Ali","year":"2015","journal-title":"Am. J. Neuroradiol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0015","first-page":"894","article-title":"Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma. Otolaryngology--head and neck surgery: Otolaryngol","volume":"153","author":"Altman","year":"2015","journal-title":"Head Neck Surg."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578752_bb0020","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","article-title":"Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?","volume":"26","author":"Apetoh","year":"2015","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578752_bb0025","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0030","first-page":"697","article-title":"Cost-utility of nivolumab plus ipilimumab in first-line treatment of advanced melanoma in the united states: an analysis using long-term overall survival data from checkmate 067","volume":"6","author":"Baker","year":"2022","journal-title":"Pharmacoecon"},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578752_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210031","article-title":"Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy","volume":"103","author":"Beecher","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00415-025-12902-x","article-title":"Neurological manifestations in patients with VEXAS syndrome","volume":"272","author":"Bert-Marcaz","year":"2025","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WNF.0000000000000464","article-title":"Severe demyelinating polyneuropathy and cranial neuropathy during Avelumab treatment of metastatic Merkel cell carcinoma","volume":"44","author":"Bili\u0107","year":"2021","journal-title":"Clin. Neuropharmacol."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578752_bb0050","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JOP.18.00250","article-title":"First-line therapies for metastatic lung adenocarcinoma without a driver mutation","volume":"14","author":"Bodor","year":"2018","journal-title":"J. Oncol. Pract."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2025","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578752_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/01658107.2017.1291686","article-title":"A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer","volume":"41","author":"Carrera","year":"2017","journal-title":"Neuroophthalmology"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0065","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/medicina60050728","article-title":"Autoimmune encephalitis following checkpoint inhibitor therapy in a patient with metastatic melanoma in complete remission","volume":"60","author":"Civardi","year":"2024","journal-title":"Medicina"},{"issue":"18","key":"10.1016\/j.jneuroim.2025.578752_bb0070","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-15-2569","article-title":"Molecular pathways: immune checkpoint antibodies and their toxicities","volume":"22","author":"Cousin","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578752_bb0075","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000519226","article-title":"Lower cranial nerve palsies in the COVID-19 pandemic: a 10-case series of intensive care unit patients","volume":"85","author":"Decavel","year":"2022","journal-title":"Eur. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mdc3.14003","article-title":"Autoimmune movement disorders complicating treatment with immune checkpoint inhibitors","volume":"11","author":"Dinoto","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578752_bb0090","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578752_bb0095","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neurol.2024.08.007","article-title":"Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: a mini-review","volume":"180","author":"Farina","year":"2024","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0100","first-page":"119","article-title":"Association of vitiligo with immune-checkpoint inhibitor therapy: a systematic review","volume":"18","author":"Fleshner","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7375947","article-title":"Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin\u00ae proteins","volume":"2020","author":"Foord","year":"2020","journal-title":"J Immunol Res"},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578752_bb0110","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0115","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12883-025-04268-4","article-title":"Serum vitamin D levels in patients with bell\u2019s palsy: a systematic review and meta-analysis","volume":"25","author":"Foroughi","year":"2025","journal-title":"BMC Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578752_bb0120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune checkpoint inhibitor-associated optic neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1016\/j.jneuroim.2025.578752_bb0125","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16547","article-title":"Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis","volume":"32","author":"Gelibter","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0140","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-018-05032-8","article-title":"A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers","volume":"9","author":"Gettinger","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578752_bb0150","first-page":"315","article-title":"Immune checkpoint inhibitor-associated celiac disease: a retrospective analysis and literature review","volume":"12","author":"Gupta","year":"2024","journal-title":"Diseases (Basel, Switzerland)"},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0155","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41423-019-0224-2","article-title":"Targeting natural killer cells in solid tumors","volume":"16","author":"Habif","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","article-title":"CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions","volume":"69","author":"Hashimoto","year":"2018","journal-title":"Annu. Rev. Med."},{"issue":"14","key":"10.1016\/j.jneuroim.2025.578752_bb0165","first-page":"3484","article-title":"U.S. FDA approval summary: Nivolumab for treatment of Unresectable or metastatic melanoma following progression on Ipilimumab","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Ass. Cancer Res."},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578752_bb0170","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112436","article-title":"PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion","volume":"42","author":"Hope","year":"2023","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578752_bb0180","article-title":"Immune checkpoint inhibitor-induced Guillain Barre syndrome: a single-institution case report and narrative review","volume":"16","author":"Idogun","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.jneuroim.2025.578752_bb0190","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s13256-024-04852-1","article-title":"Immune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report","volume":"18","author":"Jung","year":"2024","journal-title":"J. Med. Case Rep."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578752_bb0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1334718","article-title":"Immune checkpoint inhibitor-induced subacute cutaneous lupus erythematosus: a case report and review of the literature","volume":"11","author":"Khorasanchi","year":"2024","journal-title":"Front. Med."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578752_bb0220","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"16","key":"10.1016\/j.jneuroim.2025.578752_bb0230","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578752_bb0235","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2025.578752_bb0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.05.022","article-title":"Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series","volume":"117","author":"Lemasson","year":"2019","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"key":"10.1016\/j.jneuroim.2025.578752_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107764","article-title":"Natural killer cell exhaustion in lung cancer","volume":"96","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578752_bb0250","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/00207454.2020.1831489","article-title":"Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma","volume":"132","author":"Makri","year":"2022","journal-title":"Int. J. Neurosci."},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578752_bb0255","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578752_bb0260","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe neurologic complications of immune checkpoint inhibitors: a single-center review","volume":"265","author":"Mancone","year":"2018","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578752_bb0265","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mus.23830","article-title":"Multifocal radiculoneuropathy during ipilimumab treatment of melanoma","volume":"48","author":"Manousakis","year":"2013","journal-title":"Muscle Nerve"},{"issue":"16","key":"10.1016\/j.jneuroim.2025.578752_bb0270","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0285","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000524114","article-title":"Third cranial nerve palsy after monoclonal antibody therapy for lung cancer: a case report","volume":"13","author":"Missori","year":"2022","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.jneuroim.2025.578752_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.70070","article-title":"Immune checkpoint inhibitor-induced autoimmune limbic encephalitis with positivity for anti-Hu antibodies in a patient with small-cell lung cancer: a case report and literature review","volume":"12","author":"Nakahara","year":"2024","journal-title":"Respirol. Case Rep."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578752_bb0300","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"7","key":"10.1016\/j.jneuroim.2025.578752_bib491","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1242\/jcs.180885","article-title":"HDAC6 regulates the dynamics of lytic granules in cytotoxic T lymphocytes","volume":"129","author":"N\u00fa\u00f1ez-Andrade","year":"2016","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0305","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10637-021-01186-3","article-title":"Relapsing polychondritis after treatment with PD-1 blockade","volume":"40","author":"Ogimoto","year":"2022","journal-title":"Investig. New Drugs"},{"issue":"9","key":"10.1016\/j.jneuroim.2025.578752_bb0310","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","article-title":"Peripheral nervous system immune-related adverse events due to checkpoint inhibition","volume":"20","author":"O\u2019Hare","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol. Int. Off. J. Japan. Soc. Allergol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0320","first-page":"73","article-title":"Ocular motor mononeuropathies in diabetes mellitus: a brief review","volume":"133","author":"Pantazopoulos","year":"2025","journal-title":"Exp. Clin. Endocrinol. Diabet. Off. J. German Soc. Endocrinol. [and] German Diabetes Assoc."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1417444","article-title":"Sj\u00f6gren syndrome induced by anti PDL-1 treatment for TNBC: case report and review of literature","volume":"15","author":"Pellegrino","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578752_bb0330","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1007\/s00415-024-12660-2","article-title":"Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients","volume":"271","author":"Pichon","year":"2024","journal-title":"J. Neurol."},{"issue":"21","key":"10.1016\/j.jneuroim.2025.578752_bb0335","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0340","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578752_bb0345","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41423-021-00750-4","article-title":"Activation or exhaustion of CD8+ T cells in patients with COVID-19","volume":"18","author":"Rha","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0350","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1186\/s12885-019-6444-0","article-title":"Ramsay-hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report","volume":"19","author":"Sakoh","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578752_bb0355","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41422-020-0277-x","article-title":"The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity","volume":"30","author":"Schnell","year":"2020","journal-title":"Cell Res."},{"issue":"6316","key":"10.1016\/j.jneuroim.2025.578752_bb0360","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science (New York, N.Y.)"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0365","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CND.0000000000000495","article-title":"Acute multiple cranial neuropathies in chronic inflammatory demyelinating polyneuropathy: a case report and scoping review of the literature","volume":"26","author":"Shahjouei","year":"2024","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578752_bb0370","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.mayocp.2018.01.001","article-title":"Multiple cranial neuropathies from Nivolumab in a patient with metastatic hepatocellular carcinoma","volume":"93","author":"Siegel","year":"2018","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578752_bb0375","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","article-title":"A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells","volume":"166","author":"Singer","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578752_bb0380","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/WNO.0000000000001148","article-title":"Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","volume":"41","author":"Sun","year":"2021","journal-title":"J. Neuro-Ophthalmol."},{"issue":"2","key":"10.1016\/j.jneuroim.2025.578752_bb0385","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1159\/000516275","article-title":"Optic perineuritis associated with nivolumab treatment for non-small cell lung cancer","volume":"14","author":"Takada","year":"2021","journal-title":"Case Rep. Oncol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578752_bb0390","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Nat. Comp. Cancer Network: JNCCN"},{"issue":"10","key":"10.1016\/j.jneuroim.2025.578752_bb0395","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1002\/lary.31459","article-title":"Sudden deafness and vestibulopathy in a patient with antibody treatment for metastatic lung cancer","volume":"134","author":"Trache","year":"2024","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578752_bb0400","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578752_bb0405","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1158\/1940-6207.CAPR-17-0108","article-title":"PD-1 blockade prevents the development and progression of carcinogen-induced oral premalignant lesions","volume":"10","author":"Wang","year":"2017","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"6","key":"10.1016\/j.jneuroim.2025.578752_bb0410","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578752_bb0415","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578752_bb0420","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/CJI.0000000000000310","article-title":"Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report","volume":"43","author":"Willegers","year":"2020","journal-title":"J. Immunother."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0425","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40425-016-0170-9","article-title":"Acute visual loss after ipilimumab treatment for metastatic melanoma","volume":"4","author":"Wilson","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"5899","key":"10.1016\/j.jneuroim.2025.578752_bb0430","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.jneuroim.2025.578752_bb0435","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"86","key":"10.1016\/j.jneuroim.2025.578752_bb0440","doi-asserted-by":"crossref","first-page":"eade3369","DOI":"10.1126\/sciimmunol.ade3369","article-title":"In vitro modeling of CD8+ T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40","volume":"8","author":"Wu","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jneuroim.2025.578752_bb0450","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578752_bb0455","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CJI.0000000000000254","article-title":"Facial palsy induced by checkpoint blockade: a single center retrospective study","volume":"42","author":"Yuen","year":"2019","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.jneuroim.2025.578752_bb0460","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jneuroim.2025.578752_bb0465","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/CJI.0000000000000184","article-title":"Development of bell\u2019s palsy after treatment with Ipilimumab and Nivolumab for metastatic melanoma: a case report","volume":"41","author":"Zecchini","year":"2018","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.jneuroim.2025.578752_bb0470","doi-asserted-by":"crossref","DOI":"10.1177\/11206721231222659","article-title":"Bilateral retrobulbar optic neuritis combined with optic perineuritis associated with atezolizumab treatment for small cell lung carcinoma","volume":"34","author":"Zhang","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jneuroim.2025.578752_bb0475","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0480","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1448728","article-title":"A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578752_bb0490","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572825002334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:41:22Z","timestamp":1772836882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572825002334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":96,"alternative-id":["S0165572825002334"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578752","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cranial neuropathies related to immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578752"}}